Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-23T13:17:51.418Z Has data issue: false hasContentIssue false
  • English
  • Français

Parasite vaccines – recent progress and problems associated with their development

Published online by Cambridge University Press:  02 February 2007

D. P. KNOX  and
D. L. REDMOND
D. P. KNOX
Affiliation:
Moredun Research Institute, International Research Centre, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, Scotland, UK.
D. L. REDMOND
Affiliation:
Moredun Research Institute, International Research Centre, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, Scotland, UK.
Get access Rights & Permissions [Opens in a new window]

Extract

The treatment and prevention of parasitism in both humans and livestock continues to rely almost exclusively on the use of antiparasitic drugs – an approach which has limitations, particularly as reinfection, which occurs rapidly in endemic regions, is not prevented. In addition, the widespread appearance of drug-resistant parasites of animals (Kaplan, 2004;) together with emerging evidence of resistance problems in human parasites (Fallon et al. 1995; Ismail et al. 1996; De Clerq et al. 1997; East African Network for Monitoring Antimalarial Treatment, 2003), emphasise the importance of developing alternative methods of control, with anti-parasite vaccines a prime target.

Keywords

Parasitevaccinationrecombinantsub-unit vaccine
Type
Overview
Information
Parasitology , Volume 133 , Supplement S2: Parasite Vaccines , October 2006 , pp. S1 - S8
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Barnes, E. H., Dobson, R. J. and Barger, I. A. ( 1995). Worm control and anthelmintic resistance: adventures with a model. Parasitology Today 11, 56–63.CrossRefGoogle Scholar
Britton, C. and Murray, L. ( 2006). Using Caenorhabditis elegans for functional analysis of genes of parasitic nematodes. International Journal for Parasitology 36, 651–659.CrossRefGoogle Scholar
Bungiro, R. D. Jr, Greene, J., Kruglov, E. and Cappello, M. ( 2001). Mitigation of hookworm disease by immunization with soluble extracts of Ancylostoma ceylanicum. Journal of Infectious Diseases 183, 1380–1387.CrossRefGoogle Scholar
Buxton, D. and Innes, E. A. ( 1995). A commercial vaccine for ovine toxoplasmosis. Parasitology 110, S11–S16.CrossRefGoogle Scholar
Capron, M. and Capron, A. ( 1994). Immunoglobulin E and effector cells in schistosomiasis. Science 264, 1876–1877.CrossRefGoogle Scholar
Colley, D. G., LoVerde, P. T. and Savioli, L. ( 2001). Medical helminthology in the 21st century. Science 293, 1437–1438.CrossRefGoogle Scholar
Cornelissen, A. W. and Schetters, T. P. ( 1996). Vaccines against protozoal diseases of veterinary importance. FEMS Immunology and Medical Microbiology 15, 61–72.CrossRefGoogle Scholar
Dalton, J. P., Brindley, P. J., Knox, D. P., Brady, C. P., Hotez, P. J., Donnelly, S., O'Neill, S. M., Mulcahy, G. and Loukas, A. ( 2003). Helminth vaccines: from mining genomic information for vaccine targets to systems used for protein expression. International Journal for Parasitology 33, 621–640.CrossRefGoogle Scholar
Dalton, J. P., McGonigle, S., Rolph, T. P. and Andrews, S. J. ( 1996). Induction of protective immunity in cattle against infection with Fasciola hepatica by vaccination with cathepsin L proteinase and haemoglobin. Infection and Immunity 64, 5066–5074.Google Scholar
De Clerq, D., Sacko, M., Behnke, J., Gilbert, F., Dorny, P. and Vercruysse, J. ( 1997). Failure of mebenazole in treatment of human hookworm infections in the southern region of Mali. American Journal of Tropical Medicine and Hygiene 57, 25–30.CrossRefGoogle Scholar
Doolan, D. L. and Hoffman, S. L. ( 2002). Nucleic acid vaccines against malaria. Chemical Immunology 80, 308–321.CrossRefGoogle Scholar
EAST AFRICAN NETWORK FOR MONITORING ANTIMALARIAL TREATMENT (EANMAT) (2003). The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Tropical Medicine and International Health 8, 860–867.
Ellis, J., Ozaki, L. S., Gwadz, R. W., Cochrane, A. H., Nussenzweig, V., Nussenzweig, R. S. and Godson, G. N. ( 1983). Cloning and expression in E. coli of the malarial sporozoite surface antigen gene from Plasmodium knowlesi. Nature 302, 536–538.Google Scholar
Fallon, P. G., Sturrock, R. F., Niang, A. C. and Doenhoff, M. J. ( 1995). Short report: diminished susceptibility of praziquantel in a Senegal isolate of Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene 53, 61–62.CrossRefGoogle Scholar
Ferry, G. ( 2000). First DNA malaria vaccine on trial in Africa. Current Biology 10, R810–R811.CrossRefGoogle Scholar
Fonseca, C. T., Brito, C. F., Alves, J. B. and Oliveira, S. C. ( 2004). IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine 22, 503–510.CrossRefGoogle Scholar
Good, M. F. ( 2005). Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends in Parasitology 26, 295–297.CrossRefGoogle Scholar
Good, M. F., Stanisic, D., Xu, H., Elliot, S. and Wykes, M. ( 2004). The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunological Reviews 201, 254–267.CrossRefGoogle Scholar
Haslam, S. M., Coles, G. C., Munn, E. A., Smith, T. S., Smith, H. F., Morris, H. R. and Dell, A. ( 1996). Haemonchus contortus glycoproteins contain N-linked oligosaccharides with a novel highly fucosylated core structure. Journal of Biological Chemistry 271, 30561–30570.CrossRefGoogle Scholar
Hoffman, K. F., James, S. L., Cheever, A. W. and Wynn, T. A. ( 1999). Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni. Journal of Immunology 163, 927–938.Google Scholar
Hoffman, S. L., Goh, L. M., Luke, T. C., Schneider, I., Le, T. P., Doolan, D. L., Sacci, J., de la Vega, P., Dowler, M., Paul, C., Gordon, D. M., Stoute, J. A., Church, L. W., Sedegah, M., Heppner, D. G., Ballou, W. R. and Richie, T. L. ( 2002). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. Journal of Infectious Diseases 185, 1155–1164.CrossRefGoogle Scholar
Holmgren, J., Lycke, N. and Czerkinsky, C. ( 1993). Cholera toxin and cholera B subunit as oral-mucosal adjuvants and antigen-vector systems. Vaccine 11, 1179–1184.CrossRefGoogle Scholar
Hotez, P. J., Zhan, B., Bethony, J. M., Loukas, A., Williamson, A., Goud, G. N., Hawdon, J. M., Dobardzic, A., Dobardzic, R., Ghosh, K., Bottazzi, M. E., Mendez, S., Zook, B., Wang, Y., Liu, S., Essiet-Gibson, I., Chung-Debose, S., Xiao, S., Knox, D., Meagher, M., Inan, M., Correa-Oliviera, R., Vilk, P., Shepherd, H. R., Brandt, W. and Russell, P. K. ( 2003). Progress in the development of a recombinant vaccine for human hookworm disease: The Human Hookworm Vaccine Initiative. International Journal for Parasitology 33, 1245–1258.CrossRefGoogle Scholar
Ismail, M., Metwally, A., Farghaly, A., Bruce, J., Tao, L. F. and Bennett, J. L. ( 1996). Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. American Journal of Tropical Medicine and Hygiene 55, 214–218.CrossRefGoogle Scholar
Jarrett, W. F. H., Jennings, F. W., Martin, B., McIntyre, W. I. M., Mulligan, W., Sharp, N. C. C. and Urquhart, G. M. ( 1958). A field trial of a parasitic bronchitis vaccine. Veterinary Record 70, 451–454.Google Scholar
Kemp, D. J., Coppel, R. L., Cowman, A. F., Saint, R. B., Brown, G. V. and Anders, R. F. ( 1983). Expression of Plasmodium falciparum blood-stage antigens in Escherichia coli: detection with antibodies from immune humans. Proceedings of the National Academy of Sciences, USA 80, 3787–3791.CrossRefGoogle Scholar
Lightowlers, M. W., Rolfe, R. and Gauci, C. G. ( 1996). Taenia saginata: vaccination against cysticercosis in cattle with recombinant oncosphere antigens. Experimental Parasitology 84, 330–338.CrossRefGoogle Scholar
Lillehoj, H. S., Ding, X., Dalloul, R. A., Sato, T., Yasuda, A. and Lillehoj, E. P. ( 2005). Embryo vaccination against Eimeria tenella and E. acervulina infections using recombinant proteins and cytokine adjuvants. Journal of Parasitology 91, 666–673.Google Scholar
Lofthouse, S. A., Andrews, A. E., Elhay, M. J., Bowles, V. M., Meeusen, E. N. T. and Nash, A. D. ( 1996). Cytokines as adjuvants for ruminant vaccines. International Journal for Parasitology 26, 835–842.CrossRefGoogle Scholar
Kaplan, R. M. ( 2004). Drug resistance in nematodes of veterinary importance: a status report. Trends in Parasitology 20, 477–481.CrossRefGoogle Scholar
Mendez, S., Gurunathan, S., Kamhawi, S., Belkaid, Y., Moga, M. A., Skeiky, Y. A., Campos-Neto, A., Reed, S., Seder, R. A. and Sacks, D. ( 2001). The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. Journal of Immunology 166, 5122–5128.CrossRefGoogle Scholar
Mendez, S., Zhan, B., Goud, G., Ghosh, K., Dobardzic, A., Wu, W., Liu, S., Deumic, V., Dobardzic, R., Liu, Y., Bethony, J. and Hotez, P. J. ( 2005). Effect of combining the larval antigens Ancylostoma secreted protein 2 (ASP-2) and metalloprotease 1 (MTP-1) in protecting hamsters against hookworm infection and disease caused by Ancylostoma ceylanicum. Vaccine 23, 3123–3130.CrossRefGoogle Scholar
Miller, T. A. ( 1978). Industrial development and field use of the canine hookworm vaccine. Advances in Parasitology 16, 333–342.CrossRefGoogle Scholar
Mueller, A. K., Labaied, M., Kappe, S. H. and Matuschewski, K. ( 2005). Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 113–114.CrossRefGoogle Scholar
Nadim, A., Javadian, E., Tahvildar-Bidruni, G. and Ghorbsni, M. ( 1983). Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bulletin de la Société de Pathologie Exotique et de Sas Filiales 76, 377–383.Google Scholar
Nyame, A. K., Lewis, F. A., Doughty, B. L., Correa-Oliveira, R. and Cummings, R. D. ( 2003). Immunity to schistosomiasis: glycans are potential antigenic targets for immune intervention. Experimental Parasitology 104, 1–13.CrossRefGoogle Scholar
Pearce, E. J. ( 2003). Progress towards a vaccine for schistosomiasis. Acta Tropica 86, 309–313.CrossRefGoogle Scholar
Richie, T. L. and Saul, A. ( 2002). Progress and challenges for malaria vaccines. Nature 415, 694–701.CrossRefGoogle Scholar
Richter, D., Incani, R. N. and Harn, D. A. ( 1996). Lacto-N- fucopentaose III (Lewis x), a target of the antibody response in mice vaccinated with irradiated cercariae of Schistosoma mansoni. Infection and Immunity 64, 1826–1831.Google Scholar
Rickard, M. D., Harrison, G. B., Heath, D. D. and Lightowlers, M. W. ( 1995). Taenia ovis recombinant vaccine –‘quo vadit’. Parasitology 110, S5–S9.CrossRefGoogle Scholar
Sekiya, K. ( 1983). Effects of Bordatella pertussis components on IgE and IgG1 responses. Microbiology and Immunology 27, 905–915.CrossRefGoogle Scholar
Sharma, R. L., Bhat, T. K. and Dhar, D. N. ( 1981). Control of sheep lungworm in India. Parasitology Today 4, 33–36.Google Scholar
Tongren, J. E., Zavala, F., Roos, D. S. and Riley, E. M. ( 2004). Malaria vaccines: if at first you don't succeed …. Trends in Parasitology 20, 604–610.CrossRefGoogle Scholar
Weiss, R., Leitner, W. W., Scheiblhofer, S., Chen, D., Bernhaupt, A., Mostbock, S., Thalhamer, J. and Lyon, J. A. ( 2000). Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infection and Immunity 68, 5914–5919.CrossRefGoogle Scholar
Willadsen, P. ( 2004). Anti-tick vaccines. Parasitology 129, S367–S387.CrossRefGoogle Scholar
Willadsen, P., Smith, D., Cobon, G. and Hungerford, J. ( 1995). Commercialisation of a recombinant vaccine against Boophilus microplus. Parasitology 110, S43–S50.CrossRefGoogle Scholar
Willadsen, P., Smith, D., Cobon, G. and McKenna, R. V. ( 1996). Comparative vaccination of cattle against Boophilus microplus with recombinant antigen Bm86 alone or in combination with recombinant Bm91. Parasite Immunology 18, 241–246.CrossRefGoogle Scholar
Williams, G. M., Sleigh, A. C., Li, Y., Feng, Z., Davis, G. M., Chen, H., Ross, A. G., Bergquist, R. and McManus, D. P. ( 2002). Mathematical modelling of schistosomiasis japonica: comparison of control strategies in the People's Republic of China. Acta Tropica 82, 253–262.CrossRefGoogle Scholar
Wilson, R. A. and Coulson, P. S. ( 1999). Strategies for a schistosome vaccine: can we manipulate the immune response effectively? Microbes and Infection 1, 535–543.Google Scholar
Wuhrer, M., Dennis, R. D., Doenhoff, M. J. and Geyer, R. ( 2000). A fucose-containing epitope is shared by a keyhole limpet haemocyanin and Schistosoma mansoni glycosphingolipids. Molecular and Biochemical Parasitology 110, 237–246.CrossRefGoogle Scholar
Wynn, T. A. and Hoffman, K. F. ( 2000). Defining a schistosomiasis vaccination strategy – is it really Th1 versus Th2? Parasitology Today 16, 497–501.Google Scholar
You, Z., Huang, X., Hester, J., Toh, H. C. and Chen, S. Y. ( 2001). Targeting dendritic cells to enhance DNA vaccine potency. Cancer Research 61, 3704–3711.Google Scholar